Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PEPD | P12955 | 3/20 | 0.47 |
| ▸ | XPNPEP1 | Q9NQW7 | 2/20 | 0.47 |
| ▸ | DPP4 | P27487 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6563446 | 0.99 | PEPD (0.46) | PEPDXPNPEP1DPP4POLBFKBP1A | |
| SCHEMBL7378318 | 0.86 | ACE (0.55) | PEPDDPP4LMNARAB9AKDM4E | |
| SCHEMBL7378326 | 0.86 | ACE (0.55) | PEPDDPP4LMNARAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL6338692 | 0.84 | ACE (0.54) | PEPDDPP4LMNARAB9AKDM4E | |
| Hydrochloric Acid SCHEMBL11337063 | 0.83 | DPP4 (0.46) | PEPDDPP4SMN1; SMN2LMNAKDM4E | |
| SCHEMBL27015548 | 0.83 | PEPD (0.49) | PEPDXPNPEP1POLBFKBP1ASMN1; SMN2 | |
| SCHEMBL31448343 | 0.81 | ACE (0.50) | PEPDDPP4LMNAKDM4E | |
| SCHEMBL13921121 | 0.81 | PEPD (0.54) | PEPDXPNPEP1POLBFKBP1ALMNA | |
| SCHEMBL17040270 | 0.81 | PEPD (0.54) | PEPDXPNPEP1POLBFKBP1ALMNA | |
| SCHEMBL20471043 | 0.81 | PEPD (0.54) | PEPDXPNPEP1POLBFKBP1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6774110-B2 | ANTITHROMBOTIC ACTIVITY AND HIGH ORAL BIOAVAILABILITY; E.G. N-AMINOSULFONYL-D-DIPHENYLALANYL-L-PROLYL-((4-AMIDINOPHENYL)METHYL)AMIDE | LG LIFE SCIENCES LTD. (KR) | 2004-08-10 | — | — | US | disclosed |
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | LG LIFE SCIENCES LTD. (KR) | 2002-11-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020169113-A1 | Orally available peptidic thrombin inhibitors | F2, SERPINC1, TFPI | PEPD 13/4885XPNPEP1 64/4885DPP4 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.